Placid Jover
Known title: See "Remarks"CIK: 0002026165
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▲ Buy | Option Exercise | 12,827 | — | 8/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 12,827 | $447K | 8/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 14,150 | — | 3/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 14,150 | $448K | 3/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,053 | $92K | 8/1/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 12,827 | — | 8/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.